Precision Optics Reports Third Quarter Fiscal Year 2025 Financial Results

Rhea-AI Summary

Precision Optics Corporation (NASDAQ: POCI) reported Q3 FY2025 financial results with significant challenges and strategic developments. Revenue declined to $4.2 million from $5.2 million year-over-year, with production revenue at $3.3 million and engineering revenue at $0.9 million. The company faced setbacks with gross margins dropping to 10.0% from 35.5%, resulting in a net loss of ($2.1) million. Despite challenges, POCI secured a Main Purchase Agreement with a top-tier aerospace company, guaranteeing minimum purchases of nearly $4 million annually through 2026. The company launched the Unity Imaging Platform for endoscopic imaging devices and completed a $5.1 million common stock offering. Production issues with a single-use cystoscope line were resolved, with doubled throughput after February restart. Management expects improved Q4 performance with sequential revenue growth and break-even or better adjusted EBITDA.

Positive

• Secured Main Purchase Agreement with aerospace company guaranteeing ~$4M annual purchases through 2026
• Record production backlog with over $6M in aerospace orders
• Successfully doubled pre-shutdown throughput on cystoscope production line after restart
• Launched Unity Imaging Platform for endoscopic imaging devices
• Raised $5.1M through common stock offering for facility expansion
• Added two experienced executives to Board of Directors

Negative

• Revenue declined 20% YoY to $4.2M from $5.2M
• Gross margins dropped significantly to 10.0% from 35.5% YoY
• Net loss widened to $2.1M from $0.3M YoY
• Adjusted EBITDA declined to -$1.3M from $0.1M YoY
• Production issues forced temporary shutdown of cystoscope production line
• Engineering revenue decreased by 61% to $0.9M from $2.3M YoY

Insights

Financial Analyst

Precision Optics reports worrying Q3 results with significant margin compression and deepening losses despite strategic initiatives.

Precision Optics' Q3 FY2025 results reveal concerning trends across multiple financial metrics. Revenue decreased to $4.2 million, down 19.2% year-over-year and 6.7% sequentially. While production revenue showed modest growth to $3.3 million (10% YoY), engineering revenue collapsed to $0.9 million - a steep 60.9% decline from the $2.3 million in the same quarter last year.

The most alarming metric is gross margin deterioration to just 10%, compared to 35.5% a year ago and 23.6% in the previous quarter. Management attributed this to temporary production issues with their single-use cystoscope line, which required significant resources to address and forced a production pause. This operational challenge directly contributed to the widening net loss of $2.1 million versus $0.3 million in Q3 FY2024.

The adjusted EBITDA figure of -$1.3 million represents a substantial decline from the positive $0.1 million in the prior-year period. This cash burn rate is concerning, though the company did secure $5.1 million through a common stock offering during the quarter.

On a more positive note, the company has implemented significant strategic initiatives that could improve future performance, including a Main Purchase Agreement with an aerospace customer guaranteeing nearly $4 million in annual orders through 2026, and a record production backlog exceeding $6 million. Management is projecting sequential revenue growth and break-even or better adjusted EBITDA for Q4 2025, suggesting they believe the production issues have been successfully addressed.

The launch of the Unity Imaging Platform represents a potentially significant product advancement that could streamline development and production of endoscopic imaging devices, though its financial impact remains to be seen.

Manufacturing Operations Expert

Manufacturing issues severely impacted financial performance, but corrective actions should drive recovery in coming quarters.

The production challenges Precision Optics faced during Q3 2025 reveal significant operational issues that directly affected the company's financial performance. The temporary shutdown of their single-use cystoscope production line due to low initial yields created a cascading effect throughout their operations. This manufacturing disruption is directly responsible for the dramatic drop in gross margins from 35.5% to just 10% year-over-year.

From an operations perspective, the reallocation of significant internal resources to address these yield problems demonstrates a reactive rather than proactive quality management system. While management successfully restarted production in February with improved yields, the financial damage was already done for the quarter. The doubling of pre-shutdown throughput is encouraging but came too late to salvage Q3 results.

The aerospace production program's growth and transition of two development programs into production phases create additional operational complexity during this recovery period. Managing multiple production ramp-ups simultaneously while resolving quality issues requires exceptional operational discipline. The company appears to be investing appropriately in production capacity expansion, supported by their recent $5.1 million capital raise.

The launch of the Unity Imaging Platform represents a strategic shift toward modular design, which typically simplifies manufacturing processes and reduces production variability. This approach should help prevent similar yield issues in future product lines by standardizing components and processes.

Management's projection of sequential revenue growth and break-even adjusted EBITDA for Q4 suggests confidence in their operational improvements. However, the company needs to demonstrate sustained manufacturing excellence to rebuild investor confidence after this significant operational misstep. The $6 million backlog provides a solid foundation, but execution will be critical.

Conference Call Scheduled for today, May 15, 2025, at 5:00pm ET.

GARDNER, Mass., May 15, 2025 (GLOBE NEWSWIRE) -- Precision Optics Corporation, Inc. (NASDAQ: POCI), a leading designer and manufacturer of advanced optical instruments for the medical and defense/aerospace industries, announced operating results on an unaudited basis for its third quarter fiscal year 2025 for the period ended March 31, 2025.

Q3 2025 Financial Highlights (3 Months Ended March 31, 2025):

• Revenue was $4.2 million compared to $5.2 million in the same quarter of the previous fiscal year and compared to $4.5 million in the most recent sequential quarter.
• Production revenue was $3.3 million compared to $3.0 million in the same quarter of the previous fiscal year and compared to $3.3 million in the most recent sequential quarter.
• Engineering revenue was $0.9 million compared to $2.3 million in the same quarter of the previous fiscal year and compared to $1.2 million in the most recent sequential quarter.
• Gross margins were 10.0% compared to 35.5% in the same quarter of the previous year and compared to 23.6% in the most recent sequential quarter.
• Net loss for the quarter was ($2.1) million, compared to $(0.3) million in the same quarter of the previous year, and compared to $(1.0) million in the most recent sequential quarter.
• Adjusted EBITDA was $(1.3) million for the quarter compared to $0.1 million in the same quarter of the previous year and compared to $(0.6) million in the most recent sequential quarter.

Recent Additional Highlights:

• Launched the Unity Imaging Platform. The platform is comprised of a CMOS endoscopic system with customization options based on existing or newly designed sub-components. This groundbreaking modular optical platform is expected to transform the development and production of endoscopic imaging devices by significantly reducing costs, time to market, and project risks.
• Entered into a Main Purchase Agreement which will govern the Company’s ongoing work with a top tier aerospace company including minimum purchase commitments of nearly $4 million per year through calendar year ending 2026.
• Appointed former Chief Marketing Officer of IBM Software, Cloud, Data and AI businesses, Buell Duncan, and former Chief Financial Officer of LeMaitre Vascular, Inc, Joseph P. “JJ” Pellegrino, Jr. to the Company’s Board of Directors.
• Closed on a $5.1 million common stock offering to, in part, expand the Company’s facilities to support expected growth.

“We achieved significant milestones this quarter leading to a record production backlog, backed by the execution of a Main Purchase Agreement with a top tier aerospace company. Under the terms of the agreement, our customer has agreed to minimum annual purchase order commitments of nearly $4 million for both 2025 and 2026. This order commitment, and our backlog for this product of over $6 million dollars, provides us with current ample demand for our growing production schedule,” commented Precision Optics' CEO, Joseph Forkey.

“During the quarter, we experienced low initial yields on our single-use cystoscope production line, forcing us to temporarily pause production. We utilized significant internal resources to get the situation corrected. Unfortunately, our gross margins suffered materially as a result. We successfully restarted the production line in February with improved yields and have now doubled our pre-shutdown throughput. The relationship with our customer remains strong. To meet this customer’s challenging demand schedule, we are adding significantly to our production capacity. Our large aerospace production program is also growing rapidly, and we have concurrently started production for two programs transitioning from product development.”   

“We have implemented a series of initiatives to drive growth, including the launch of our Unity Platform.  Improved production results and the advancement of new programs are expected to result in a positive fourth quarter, including sequential revenue growth and break-even or better adjusted EBITDA,” Forkey concluded.

The following table summarizes the third quarter and year-to-date (unaudited) results for the periods ended March 31, 2025, and 2024:

		Three Months							Nine Months
		Ended March 31							Ended March 31
			2025			2024				2025			2024
Revenues		$4,185,968			$5,242,579				$12,909,928			$14,388,123
Gross Profit			417,975			1,858,737				2,605,247			4,773,324
Stock Compensation Expenses			714,662			258,214				1,172,233			749,391
Other			1,741,598			1,859,050				5,628,261			5,391,915
Total Operating Expenses			2,456,261			2,177,264				6,800,494			6,141,306
Operating Income (Loss)			(2,038,286)			(258,527)				(4,195,247)			(1,367,982)
Net Income (Loss)			(2,096,762)			(317,055)				(4,377,689)			(1,540,272)
Income (Loss) per Share
	Basic & Fully Diluted	$(0.30)			$(0.05)				$(0.67)			$(0.25)
Weighted Average Common Shares Outstanding
	Basic & Fully Diluted		6,917,281			6,068,419				6,491,687			6,067,165

Conference Call Details
Date and Time: Thursday, May 15, 2025, at 5:00 p.m. ET.

Call-in Information: Interested parties can access the conference call by dialing (844) 735-3662 or
(412) 317-5705.

Live Webcast Information: Interested parties can access the conference call via a live webcast, which is available at https://app.webinar.net/XMqWYwq1mQa.

Replay: A teleconference replay of the call will be available for seven days, at (877) 344-7529 or (412) 317-0088, replay access code 9425811. A webcast replay will be available at https://app.webinar.net/XMqWYwq1mQa.

About Precision Optics Corporation
Founded in 1982, Precision Optics is a vertically integrated optics company primarily focused on leveraging its proprietary micro-optics, 3D imaging and digital imaging technologies to the healthcare and defense/aerospace industries by providing services ranging from new product concept through mass manufacture. Utilizing its leading-edge in-house design, prototype, regulatory and fabrication capabilities as well as its Ross Optical division's high volume world-wide sourcing, inspecting and production resources, the Company is able to design and manufacture next-generation product solutions to the most challenging customer requirements. Within healthcare, Precision Optics enables next generation medical device companies around the world to meet the increasing demands of the surgical community who require more enhanced and smaller imaging systems for minimally invasive surgery as well as 3D endoscopy systems to support the rapid proliferation of surgical robotic systems. In addition to these next generation applications, Precision Optics has supplied top tier medical device companies a wide variety of optical products for decades, including complex endocouplers and specialized endoscopes. The Company is also leveraging its technical proficiency in micro-optics to enable leading edge defense/aerospace applications which require the highest quality standards and the optimization of size, weight and power. For more information, please visit www.poci.com.

Non-GAAP Financial Measures

Precision Optics has provided in this press release financial information that has not been prepared in accordance with accounting principles generally accepted in the Unites States of America (“non-GAAP”). The non-GAAP financial measure is Adjusted EBITDA (earnings before interest, taxes, depreciation and amortization). In addition to the aforementioned items, Adjusted EBITDA also excludes from Net Income (Loss) the effect of stock-based compensation.

This non-GAAP financial measure assists Precision Optics management in comparing its operating performance over time because certain items may obscure the underlying business trends and make comparisons of long-term performance difficult, as they are of a nature and/or size that occur with inconsistent frequency or relate to discrete acquisition or restructuring plans that are fundamentally different from the ongoing productivity of the Company. Precision Optics management also believes that presenting this measure allows investors to view its performance using the same measures that the Company uses in evaluating its financial and business performance and trends.

Non-GAAP financial measures should not be considered in isolation from, or as a substitute for, financial information calculated in accordance with GAAP. Investors are encouraged to review the reconciliation of non-GAAP measures to their most directly comparable GAAP financial measures. A reconciliation of the non-GAAP financial measure presented above to GAAP results has been provided in the financial tables included with this press release.

About Forward-Looking Statements
This press release contains forward-looking statements within the meaning of U.S. federal securities laws. Any statements contained herein that are not statements of historical fact may be deemed to be forward-looking statements. In addition, any statements that refer to projections, forecasts, or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words "anticipate," "believe," "continue," "could," "estimate," "expect," "intends," "may," "might," "plan," "possible," "potential," "predict," "project," "should," "would" and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. The forward-looking statements contained in this press release are based on certain assumptions and analyses made by the management of the Company in light of their respective experience and perception of historical trends, current conditions, and expected future developments and their potential effects on the Company as well as other factors they believe are appropriate in the circumstances. There can be no assurance that future developments affecting the Company will be those anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond the control of the parties), or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements, including the demand for the Company's products, global supply chains and economic activity in general and other risks and uncertainties identified in the Company's filings with the SEC. Should one or more of these risks or uncertainties materialize or should any of the assumptions being made prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as may be required under applicable securities laws.

Company Contact:
PRECISION OPTICS CORPORATION
22 East Broadway
Gardner, Massachusetts 01440-3338
Telephone: 978-630-1800

Investor Contact:
LYTHAM PARTNERS, LLC
Robert Blum
Telephone: 602-889-9700
poci@lythampartners.com

PRECISION OPTICS CORPORATION, INC. CONSOLIDATED BALANCE SHEETS (UNAUDITED)
		March 31,				June 30,
		2025				2024
ASSETS
Current Assets:
Cash and cash equivalents		$	2,547,873			$	405,278
Accounts receivable, net of allowance for credit losses of $66,833 at March 31, 2025 and $118,872 at June 30, 2024			3,425,053				3,545,491
Inventories, net			3,671,401				2,868,100
Prepaid expenses			326,524				299,364
Total current assets			9,970,851				7,118,233
Fixed Assets:
Machinery and equipment			3,408,480				3,341,194
Leasehold improvements			823,191				810,914
Furniture and fixtures			517,847				416,425
			4,749,518				4,568,533
Less—accumulated depreciation and amortization			4,215,649				4,074,960
Net fixed assets			533,869				493,573
Operating lease right-to-use asset			57,088				189,999
Patents, net			236,256				286,559
Goodwill			8,824,210				8,824,210
Total other assets			9,117,554				9,300,768
TOTAL ASSETS		$	19,622,274			$	16,912,574
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current Liabilities:
Revolving line of credit		$	–			$	1,000,000
Current portion of capital lease obligation			36,225				41,113
Current maturities of long-term debt			576,405				276,928
Accounts payable			1,873,572				1,397,313
Contract liabilities			1,665,551				1,172,350
Accrued compensation and other			800,371				840,662
Current portion of operating lease liability			57,088				178,450
Total current liabilities			5,009,212				4,906,816
Capital lease obligation, net of current portion			–				27,369
Long-term debt, net of current maturities and debt issuance costs			1,435,345				1,899,052
Operating lease liability, net of current portion			–				11,549
Total liabilities			6,444,557				6,844,786
Stockholders’ Equity:
Common stock, $0.01 par value: 50,000,000 shares authorized; issued and outstanding – 7,666,247 shares at March 31, 2025 and 6,073,939 at June 30, 2024			76,662				60,739
Additional paid-in capital			68,669,128				61,197,433
Accumulated deficit			(55,568,073	)			(51,190,384	)
Total stockholders’ equity			13,177,717				10,067,788
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY		$	19,622,274			$	16,912,574

PRECISION OPTICS CORPORATION, INC. CONSOLIDATED STATEMENTS OF OPERATIONS FOR THE NINE MONTHS ENDED MARCH 31, 2025 AND 2024 (UNAUDITED)
		Three Months Ended March 31,								Nine Months Ended March 31,
		2025				2024				2025				2024
Revenues		$	4,185,968			$	5,242,579			$	12,909,928			$	14,388,123
Cost of Goods Sold			3,767,993				3,383,842				10,304,681				9,614,799
Gross Profit			417,975				1,858,737				2,605,247				4,773,324
Research and Development Expenses			211,242				192,773				929,648				627,259
Selling, General and Administrative Expenses			2,245,018				1,924,491				5,870,846				5,514,047
Total Operating Expenses			2,456,260				2,117,264				6,800,494				6,141,306
Operating Income (Loss)			(2,038,285	)			(258,527	)			(4,195,247	)			(1,367,982	)
Interest Expense			(58,476	)			(58,528	)			(182,442	)			(172,290	)
Net Income (Loss)		$	(2,096,761	)		$	(317,055	)		$	(4,377,689	)		$	(1,540,272	)
Income (Loss) Per Share:
Basic and Fully Diluted		$	(0.30	)		$	(0.05	)		$	(0.67	)		$	(0.25	)
Weighted Average Common Shares Outstanding:
Basic and Fully Diluted			6,917,281				6,068,419				6,491,687				6,067,165

PRECISION OPTICS CORPORATION, INC. CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY FOR THE NINE MONTHS ENDED MARCH 31, 2025 AND 2024 (UNAUDITED)
		Nine Month Period Ended March 31, 2025
		Number of Shares				Common Stock				Additional Paid-in Capital				Accumulated Deficit				Total Stockholders’ Equity
Balance, July 1, 2024			6,073,939			$	60,739			$	61,197,433			$	(51,190,384	)		$	10,067,788
Issuance of common stock in registered direct offering			265,868				2,659				1,201,883				–				1,204,542
Proceeds from exercise of stock option			10,363				104				26,896				–				27,000
Stock-based compensation			–				–				149,364				–				149,364
Net loss			–				–				–				(1,311,247	)			(1,311,247	)
Balance, September 30, 2024			6,350,170				63,502				62,575,576				(52,501,631	)			10,137,447
Stock-based compensation			–				–				278,206				–				278,206
Issuance of common stock for consulting services			5,364				53				29,947				–				30,000
Net loss			–				–				–				(969,681	)			(969,681	)
Balance, December 31, 2024			6,355,534				63,555				62,883,729				(53,471,312	)			9,475,972
Issuance of common stock in registered direct offering			1,272,500				12,725				5,052,869				–				5,065,594
Proceeds from exercise of stock option			13,162				132				18,118				–				18,250
Stock-based compensation			–				–				592,964				–				592,964
Issuance of common stock for consulting services and employees			25,051				250				121,448				–				121,698
Net loss			–				–				–				(2,096,761	)			(2,096,761	)
Balance, March 31, 2025			7,666,247			$	76,662			$	68,669,128			$	(55,568,073	)		$	13,177,717

		Nine Month Period Ended March 31, 2024
		Number of Shares				Common Stock				Additional Paid-in Capital				Accumulated Deficit				Total Stockholders’ Equity
Balance, July 1, 2023			6,066,518			$	60,665			$	60,224,934			$	(48,239,007	)		$	12,046,592
Stock-based compensation			–				–				108,746				–				108,746
Net loss			–				–				–				(464,415	)			(464,415	)
Balance, September 30, 2023			6,066,518				60,665				60,333,680				(48,703,422	)			11,690,923
Stock-based compensation			–				–				382,431				–				382,431
Proceeds from the exercise of stock options			1,000				10				2,690				–				2,700
Net loss			–				–				–				(758,802	)			(758,802	)
Balance, December 31, 2023			6,067,518				60,675				60,718,801				(49,462,224	)			11,317,252
Stock-based compensation			–				–				258,214				–				258,214
Proceeds from the exercise of stock options			1,000				10				2,690				–				2,700
Net loss			–				–				–				(317,055	)			(317,055	)
Balance, March 31, 2024			6,068,518			$	60,685			$	60,979,705			$	(49,779,279	)		$	11,261,111

PRECISION OPTICS CORPORATION, INC.
RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES
ADJUSTED EBITDA
		Three Months Ended										Nine Months Ended
		March 31,										March 31,
		2025					2024					2025					2024
Net Income (loss) (GAAP)		$	(2,096,761	)			$	(317,055	)			$	(4,377,689	)			$	(1,540,272	)
Stock based compensation			714,662					258,214					1,172,232					749,391
Depreciation and amortization			62,358					52,325					159,844					156,586
Interest expense			58,476					58,528					182,442					172,290
Adjusted EBITDA (non-GAAP)		$	(1,261,265	)			$	52,012				$	(2,863,171	)			$	(462,005	)

FAQ

What were Precision Optics (POCI) Q3 2025 earnings results?

POCI reported Q3 2025 revenue of $4.2M (down from $5.2M YoY), with a net loss of $2.1M and gross margins of 10.0%. Production revenue was $3.3M and engineering revenue was $0.9M.

What major contract did POCI secure in Q3 2025?

POCI secured a Main Purchase Agreement with a top-tier aerospace company that includes minimum purchase commitments of nearly $4M per year through 2026.

How much did POCI raise in their stock offering?

POCI closed on a $5.1M common stock offering, with proceeds intended to expand company facilities to support expected growth.

What caused POCI's margin decline in Q3 2025?

Low initial yields on the single-use cystoscope production line forced a temporary production pause, significantly impacting gross margins. Production resumed in February with improved yields and doubled throughput.

What is POCI's Unity Imaging Platform?

The Unity Imaging Platform is a CMOS endoscopic system with customization options, designed to reduce costs, time to market, and project risks in endoscopic imaging device development and production.